Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg.

Kearns AK, Bilbie CL, Clarkson PM, White CM, Sewright KA, O'Fallon KS, Gadarla M, Thompson PD.

Atherosclerosis. 2008 Sep;200(1):121-5. doi: 10.1016/j.atherosclerosis.2007.12.029. Epub 2008 Feb 7.

PMID:
18261731
2.

Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance.

Ballard KD, Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, Chipkin S, Pescatello LS, Simpson K, White CM, Thompson PD.

Atherosclerosis. 2013 Sep;230(1):121-4. doi: 10.1016/j.atherosclerosis.2013.07.001. Epub 2013 Jul 13.

3.

Effect of statins on skeletal muscle function.

Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, Chipkin S, Pescatello LS, Simpson K, White CM, Thompson PD.

Circulation. 2013 Jan 1;127(1):96-103. doi: 10.1161/CIRCULATIONAHA.112.136101. Epub 2012 Nov 26.

4.

Safety and efficacy of atorvastatin in heart transplant recipients.

Patel DN, Pagani FD, Koelling TM, Dyke DB, Baliga RR, Cody RJ, Lake KD, Aaronson KD.

J Heart Lung Transplant. 2002 Feb;21(2):204-10.

PMID:
11834348
6.

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.

Gagné C, Gaudet D, Bruckert E; Ezetimibe Study Group.

Circulation. 2002 May 28;105(21):2469-75.

7.

The influence of atorvastatin on walking performance in peripheral arterial disease.

Bregar U, Poredos P, Sabovic M, Jug B, Sebestjen M.

Vasa. 2009 May;38(2):155-9. doi: 10.1024/0301-1526.38.2.155.

PMID:
19588303
8.

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.

Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL.

Clin Pharmacol Ther. 1996 Dec;60(6):687-95.

PMID:
8988072
9.

No adverse effects of statins on muscle function and health-related parameters in the elderly: an exercise study.

Panayiotou G, Paschalis V, Nikolaidis MG, Theodorou AA, Deli CK, Fotopoulou N, Fatouros IG, Koutedakis Y, Sampanis M, Jamurtas AZ.

Scand J Med Sci Sports. 2013 Oct;23(5):556-67. doi: 10.1111/j.1600-0838.2011.01437.x. Epub 2012 Jan 31.

PMID:
22288788
10.

Lovastatin increases exercise-induced skeletal muscle injury.

Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR.

Metabolism. 1997 Oct;46(10):1206-10.

PMID:
9322808
11.

Randomised study to compare the efficacy and safety of isapgol plus atorvastatin versus atorvastatin alone in subjects with hypercholesterolaemia.

Jayaram S, Prasad HB, Sovani VB, Langade DG, Mane PR.

J Indian Med Assoc. 2007 Mar;105(3):142-5, 150.

PMID:
17824470
13.

Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins.

Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD.

Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2560-6. Epub 2005 Oct 13.

14.
15.
16.

A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design.

Thompson PD, Parker BA, Clarkson PM, Pescatello LS, White CM, Grimaldi AS, Levine BD, Haller RG, Hoffman EP.

Prev Cardiol. 2010 Summer;13(3):104-11. doi: 10.1111/j.1751-7141.2009.00063.x.

17.

Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels.

Bakker-Arkema RG, Nawrocki JW, Black DM.

Atherosclerosis. 2000 Mar;149(1):123-9.

PMID:
10704623
18.

Effect of atorvastatin on energy expenditure and skeletal muscle oxidative metabolism at rest and during exercise.

Chung J, Brass EP, Ulrich RG, Hiatt WR.

Clin Pharmacol Ther. 2008 Feb;83(2):243-50. Epub 2007 Jun 6.

PMID:
17554242
19.

An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor.

Black DM, Bakker-Arkema RG, Nawrocki JW.

Arch Intern Med. 1998 Mar 23;158(6):577-84.

PMID:
9521221
20.

A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.

Illingworth DR, Crouse JR 3rd, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, Ma PT, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB; Simvastatin Atorvastatin HDL Study Group.

Curr Med Res Opin. 2001;17(1):43-50.

PMID:
11464446

Supplemental Content

Support Center